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Abstract
Background: In rhesus macaques, simian immunodeficiency virus infection is followed by expansion of enteric
viruses but has a limited impact on the gut bacteriome. To understand the longitudinal effects of HIV-1 infection on
the human gut microbiota, we prospectively followed 49 Mozambican subjects diagnosed with recent HIV-1
infection (RHI) and 54 HIV-1-negative controls for 9–18 months and compared them with 98 chronically HIV-1-
infected subjects treated with antiretrovirals (n = 27) or not (n = 71).
Results: We show that RHI is followed by increased fecal adenovirus shedding, which persists during chronic HIV-1
infection and does not resolve with ART. Recent HIV-1 infection is also followed by transient non-HIV-specific
changes in the gut bacterial richness and composition. Despite early resilience to change, an HIV-1-specific
signature in the gut bacteriome—featuring depletion of Akkermansia, Anaerovibrio, Bifidobacterium, and
Clostridium—previously associated with chronic inflammation, CD8+ T cell anergy, and metabolic disorders, can be
eventually identified in chronically HIV-1-infected subjects.
Conclusions: Recent HIV-1 infection is associated with increased fecal shedding of eukaryotic viruses, transient loss
of bacterial taxonomic richness, and long-term reductions in microbial gene richness. An HIV-1-associated
microbiome signature only becomes evident in chronically HIV-1-infected subjects.
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Background
There is cumulative evidence that the gut microbiota
plays an important role in HIV-1 pathogenesis. The
gut-associated lymphoid (GALT) and epithelial tissues
are severely and rapidly damaged following HIV-1 infec-
tion [1]. The resulting local and systemic inflammation
and loss of CD4+ T cells, chronic immune activation,
and immune deregulation [2–9] are not fully restored
with antiretroviral therapy (ART). Chronic inflamma-
tion, immune activation, and endotoxemia are linked to
the precocious development of aging-related diseases
like type 2 diabetes, cardiovascular diseases, and frailty
syndrome in people living with HIV (PLWH) [3, 10–12].
All such disorders have been associated with gut micro-
biota alterations in non-HIV-infected subjects [13–15].
It is thus conceivable that the gut microbiome might
also be involved in the premature aging of PLWH.
However, the precise mechanisms governing the inter-
play between the host immune system and HIV-1, as
well as the exact changes occurring in the gut micro-
biome following HIV-1 infection, remain to be defined.
Cross-sectional studies consistently show reduced bac-
terial diversity and enrichment in Proteobacteria in
PLWH, which are linked to lower CD4+ T cell counts
[16], higher inflammation, and increased immune activa-
tion [5, 17–19]. Previously reported associations between
Prevotella predominance and HIV-1 infection have been
shown to be confounded by HIV-1 risk group [19–22].
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Using fecal shotgun metagenomics, we previously found
that nadir CD4+ T cell count, the main predictor of clin-
ical complications in PLWH, is also a major independent
predictor of reduced microbial gene richness and gut mi-
crobial shifts in this population [23]. Such shifts include
depletion of methanogens, sulfate-reducing bacteria, and
other oxygen-sensitive syntrophic microbes, coupled with
enrichment in ROS/RNS-resistant microbes like Bacter-
oides and Proteobacteria.
Longitudinal studies in non-human primates, which
allow to control for confounders affecting human studies
have consistently reported increases in taxa from
phylum Proteobacteria, such as Actinobacillus spp. and
Aggregatibacter spp., as well as in potential pathogens
from the Mycoplasmacetae family and Staphylococ-
cus spp. following simian immunodeficiency virus (SIV)
infection [24, 25]. However, no consistent changes are
observed in other major phyla like Bacteroidetes or Fir-
micutes, suggesting that gut microbiome changes after
SIV infection are pleiotropic [24]. Furthermore, in
non-human primate models, pathogenic but not
non-pathogenic SIV infection is linked to an expansion
of the enteric virome, including Adenovirus, Picorna-
virus, and Anellovirus, which is associated with gut epi-
thelial damage, tissue inflammation, and gut leakiness
[26].
In the only longitudinal study available to date in
humans [27], the gut microbiome of 59 subjects diag-
nosed with HIV-1 infection during Fiebig I–IV stages
was enriched in phylum Bacteroidetes and depleted in
phyla Firmicutes and Proteobacteria compared to 26
HIV-negative controls. Antiretroviral treatment (ART)
initiation was associated with relative increases in Fuso-
bacteria, Proteobacteria, and Tenericutes and decreases
in Bacteroidetes and Firmicutes. Such findings are in
contrast with non-human primate data [24, 25] which
report opposite dynamics regarding Proteobacteria, as
well as with data from cross-sectional human studies [5,
18, 28, 29]. Moreover, they provide limited information
below the phylum taxonomic level, which is essential to
understand the pathophysiology of gut dysbiosis in HIV
infection and to devise future interventions on the gut
microbiome. The initiation of ART shortly after diagno-
sis did not enable a more prolonged evaluation of the
gut microbiome dynamics following HIV-1 infection. Fi-
nally, the study did not provide insights as to the role of
intestinal virus expansion after HIV-1 infection.
Here, we present the results of a prospective and con-
trolled cohort study investigating the evolution of the gut
bacteriome and of several clinically relevant eukaryotic vi-
ruses following HIV-1 infection in Mozambique. Longitu-
dinal microbiome data are compared with cross-sectional
samples from treated and non-treated chronically HIV-1-in-
fected subjects from the same setting. Gut microbiome
findings are analyzed in the context of extensive clinical and
microbiological metadata to rule out potential confounders
and are associated with a comprehensive panel of immune
markers, including inflammation, activation, gut barrier in-
tegrity, and bacterial translocation. Finally, a whole metage-
nomic analysis is performed on a subset of patients to gain
further insights into gut microbial species and functional dy-
namics following HIV-1 infection.
Results
Study subjects
Out of 4011 subjects screened for fever-like illness or
undergoing voluntary HIV-1 testing in the Manhiça Dis-
trict Hospital, Mozambique, 85 (2.1%) fulfilled criteria for
recent HIV-1 infection (RHI). Forty-nine of them plus 55
HIV-negative (NEG) individuals consented to participate
in this microbiome study (Additional file 1: Table S1). In
addition, 98 chronically HIV-1-infected subjects, 27 of
them receiving ART (CHI_ART), mainly consisting on
NVP, 3TC and AZT, and 71 ART-naive (CHI_noART),
provided a single fecal and blood sample for
cross-sectional comparisons with RHI and NEG (Add-
itional file 1: Figure S1). For such cross-sectional compari-
son, the longitudinal follow-up of RHI was divided in two
periods: before and after the first 6 months of follow-up
(RHI ≤ 6 and RHI > 6), and only data from the first sam-
ple available from each period, as well as the first sample
available from each NEG subject, were included.
At the first study visit (baseline, Table 1) chronically
HIV-1-infected subjects were older, had slightly higher
BMI scores, and were less likely to have suffered malaria
in the previous month than the remaining participants
(Table 1). As expected, compared with HIV-negative in-
dividuals, RHI subjects had lower CD4+ T cell, higher
CD8+ T cell, and lower platelet counts. There were no
significant differences between groups in the prevalence
of hepatitis B virus, syphilis, and multiple other micro-
bial determinations. Longitudinally, the RHI group
showed statistically significant decreases in CD8+ T cell
counts and viral load, together with a significant increase
in CD4+/CD8+ ratio, during the first 6 months after
HIV-1 acquisition (Additional file 1: Figure S2).
16S rRNA gene sequencing
Alpha diversity
Genus richness and diversity were not different between
cross-sectional comparison groups except for the ACE
richness numeric parameter, which was significantly
lower in HIV-negative subjects than in the remaining
groups (Fig. 1a). Longitudinally, richness and diversity
increased during the first 6 and 4months in both RHI
and NEG subjects, respectively (Fig. 1b), with similar
slopes between the two groups. Only gender was signifi-
cantly associated to differences in microbial richness and
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Table 1 Baseline subject’s characteristics
Recent HIV-1 infection Chronic HIV-1 infection HIV-Negative p value
ART-naive On ART RHI vs neg Overall
N = 202 49 71 27 55
Female gender 32 (65%) 52 (73%) 15 (55%) 43 (78%) 0.189 0.154
Age (years) 26 (20; 30) 35 (29; 45.5) 42 (36.5; 46.5) 25 (21; 37) 0.210 < 0.001
Weight (kg) 55 (49; 62) 63 (53.5; 68.5) 61 (60; 68.5) 58.5 (52; 67) 0.093 0.007
Height (cm) 160 (155; 169.7) 160 (154.2; 164) 164 (157.5; 167.5) 163.9 (160; 170.8) 0.192 0.025
BMI 21 (19.1; 23.5) 23.7 (21; 27.6) 23.3 (21.5; 25) 22.2 (18.5; 25) 0.637 < 0.001
Pregnancy 3 (6.1%) 0 0 7 (12.7%) 0.730 0.003
CD4+ T cell/mm3 572 (409; 677) 533 (430.5; 726) 460 (366; 594.5) 928 (741; 1142.8) < 0.001 < 0.001
CD8+ T cell/mm3 1229 (740; 1683) 988 (763.5; 1304) 834 (657.5; 1130) 591 (387.5; 689.7) < 0.001 < 0.001
CD4+/CD8+ 0.42 (0.23; 0.70) 0.56 (0.38; 0.79) 0.52 (0.33; 0.88) 1.65 (1.21; 2.24) < 0.001 < 0.001
HIV-1 RNA at timepoint 1 (copies/
mL)
108,220 (31,898; 273,650) 33,400 (7288; 105,200) 75 (75; 272.5) – – < 0.001
HIV-1 RNA at screening (copies/
ml)
2,752,700 (179,220; 15,078,000) – – – – –
Time since HIV-1-diagnosis, days – 1344 (977; 1737) 1814 (1463; 2302) – – 0.018
Time on ART, days – – 1257 (678; 1640) – – –
Fiebig stage at screening* III 24 (49%) – – – –
IV 7 (14.2%) – – – –
V 7 (14.2%) – – – –
VI 11 (22.6%) – – – –
White blood cells 5.8 (4.4; 6.7) 5.2 (4.2; 6.4) 3.7 (3.2; 5) 5.2 (4.4; 6.5) 0.413 < 0.001
Hemoglobin 12.1 (10.9; 13.1) 11.8 (10.4; 12.7) 11.4 (10.8; 12.7) 12.3 (11.6; 13.2) 0.409 0.114
Hematocrite 36.9 (33.5; 39.8) 35.6 (32.7; 38.5) 34.4 (33; 38) 37.7 (34.7; 40.1) 0.320 0.044
Platelets 184.5 (140.7; 230.7) 205 (174.5; 258) 192 (173.5; 216) 226 (185; 265.5) 0.004 0.028
Hepatitis B 4 (8.1%) 2 (2.8%) 3 (11.1%) 1 (1.8%) 0.173 0.125
Syphilis 2 (4.1%) 0 1 (3.7%) 4 (7.3%) 0.682 0.089
Diarrhea, previous week 7 (14.3%) 3 (4.2%) 1 (3.7%) 4 (7.3%) 0.343 0.214
Temperature (°C) 36.3 (36.2; 36.5) 36.4 (36.2; 36.4) 36.4 (36.2; 36.4) 36.2 (36.1; 36.5) 0.956 0.509
Fever, previous 24 h 7 (14.3%) 3 (4.2%) 1 (3.7%) 3 (5.4%) 0.186 0.186
Ritchie test 2 (4.1%) 2 (2.8%) 0 1 (1.81%) 0.600 0.864
Entamoeba hystolitica 2 (4.1%) 6 (8.4%) 1 (3.7%) 2 (3.6%) 1 0.733
Giardia spp 2 (4.1%) 2 (2.8%) 0 5 (9.1%) 0.438 0.236
Cryptosporidium spp 0 2 (2.8%) 0 0 1 0.635
Clostridium difficile 2 (4.1%) 0 1 (3.7%) 1 (1.8%) 0.602 0.458
Strongyloides 1 (2.0%) 0 0 1 (1.8%) 1 0.636
Malaria, prev. month 7 (14.3%) 1 (1.4%) 0 9 (16.4%) 1 < 0.001
Current malaria test 2 (4.1%) 1 (1.4%) 0 0 – 0.071
Malaria test severity 3 (1.5; 3) 4 (4; 4) NA NA – 0.071
Differences in continuous variables were evaluated using ANOVA test (except for the time since HIV-1 diagnosis, which is evaluated using a Student T test). Differences
in categorical variables were tested using the Fisher's test. The statistical significance threshold was set to P = 0.05
*Fiebig stage determination at screening visit is described in [30]. Malaria test was only performed in subjects reporting febrile symptoms. Malaria severity is
measured in a scale of 1 to 5, from light to severe
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diversity considering the baseline dataset, with men
showing significantly lower values than female. Longitu-
dinally, men showed stronger increases along follow-up
compared to females (data not shown).
Microbial genus composition
Using non-metric multi-dimensional scaling (NMDS) on
microbial phyla and genera composition data matrices,
there were no significant clustering patterns between
cross-sectional comparison groups, regardless of the
distance metric used (Additional file 1: Figure S4). Parti-
tion around medoids (PAM) algorithm did not support
microbiome clustering, and none of the metadata
variables showed a significant differential effect on gut
microbiome composition groups in PERMANOVA ana-
lyses (not shown). However, there was a statistically sig-
nificant reduction in genus beta-diversity from RHI < 6
to RHI > 6 (Additional file 1: Figure S5).
In cross-sectional group comparisons (Fig. 2), CHI_-
noART were significantly depleted in Akkermansia, Anaero-
vibrio, Bifidobacterium, and Clostridium, relative to NEG
individuals. Antiretroviral treatment exposure (CHI_ART)
was not associated with changes in abundance of such gen-
era, relative to CHI_noART. Individuals with RHI < 6
months were enriched in Haemophilus and Veillonella
relative to HIV-negative subjects. Finally, there was an
Fig. 1 Microbial genus richness and diversity indices obtained with 16S rRNA gene sequencing. a Median ± IQR values in different cross-sectional
comparison groups. Kruskal–Wallis p values are shown at the bottom of each plot. Asterisks (p values *< 0.1 and **< 0.05) highlight statistically
significant Tukey post hoc pairwise differences between groups, corrected for multiple comparisons (FDR < 0.05). b, c Linear mixed models of the
dynamics of richness and diversity indices in recently HIV-infected (RHI, red) and HIV-negative (NEG, green) subjects over time. Horizontal axes
show months after study enrollment. Each dot corresponds to a sample, and samples from the same individual through follow-up are line-
connected. Single dots correspond to individuals with no longitudinal follow-up. Thick black lines correspond to the modeled slope of each
parameter. Vertical dashed lines show the inflection point at month 6 used for modelling in b and c. Statistically, significant differences from 0
(flat slope) are shown with asterisks. p values *< 0.1 and **< 0.05
Rocafort et al. Microbiome            (2019) 7:73 Page 4 of 17
enrichment in Odoribacter and depletion in Dorea in RHI >
6months relative to RHI < 6months.
To evaluate the longitudinal evolution of microbial gen-
era, 7 coabundant microbial genus clusters were identified
(SP1 to 7, Fig. 3a, b). Only clusters SP1, 4, and 7 showed
significant longitudinal changes during follow-up, and
only in subjects with RHI (Fig. 3b). Cluster SP1, which
was associated with increased plasma levels of cytokines
involved in TNF-mediated innate responses (IL-10, IL-12,
IP-10, BAFF, CD27, Fas ligand, and TNF receptor 2), de-
creased during the first 6 months of follow-up (Fig. 3c).
Conversely, clusters SP4 and SP7, which included Odori-
bacter, Rikenellaceae unclassified, and Barnesiaellaceae
unclassified and Clostridiales unclassified, Butyricimonas,
Faecalibacterium, and Succinivibrio, respectively, in-
creased during the same period (Fig. 3b). There was no
evidence, however, that the longitudinal evolution of such
clusters was significantly different between RHI and NEG.
Clusters SP2 and SP3 did not significantly change in
abundance over time, but confirmed the aforemen-
tioned observations regarding reduced Akkermansia,
Anaerovibrio, and Clostridium in CHI_noART, rela-
tive to HIV-negative individuals. Moreover, SP2 was
negatively correlated with markers of microbial
translocation (sCD14), inflammation (IP10), and gut
integrity (IgG ASCA) (Fig. 3c).
Whole shotgun metagenome sequencing
Alpha diversity
Shotgun sequencing data also showed increasing trends
in microbial richness and Shannon diversity over time
(Additional file 1: Figure S3) in both RHI and NEG
groups, suggesting that such changes in ecological pa-
rameters were not HIV-1-specific. Differences were not
statistically significant, however, due to limited power.
Previous publications in European subjects have linked
low values of gut microbial gene richness to metabolic dys-
regulation, obesity, immune activation, and inflammation
Fig. 2 Differences in bacterial genera between groups. Box plots show median (± IQR) abundance of bacterial genera. Bacterial genera named
“unclassified” are identified by their closest taxonomic level identification. Only bacterial genera with a significantly different abundance between
groups (Kruskal–Wallis p value < 0.05) are shown. Statistically significant post hoc pairwise differences (Tukey post hoc pairwise tests corrected for
multiple comparisons, FDR < 0.05) are shown with asterisks. Only the first microbiome measurement obtained RHI < 6, RHI > 6, and NEG was
used for cross-sectional comparisons with CHI_ART and CHI_noART
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Fig. 3 (See legend on next page.)
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[13, 31, 32]. In agreement with previous reports, the gut
microbial gene richness also followed a bimodal distribu-
tion in Mozambican individuals. Samples with gene counts
above and below a gene count threshold of 444.219 genes
were categorized as high (HGC) and low gene counts
(LGCs), respectively, (Fig. 4). Whereas 63% (22/35) of the
RHI samples were included in the LGC category, only 37%
(7/19) of HIV-negative samples were LGC (Fisher’s test
p value 0.003) (Fig. 4a). At the first timepoint, 10/13
(76.9%) of RHI vs 4/8 (50%) of HIV-negative subjects (Fish-
er’s test p value 0.172) were already LGC (Fig. 4b). Eight of
13 (61.5%) subjects from the RHI group, but none of the
HIV-negative individuals showed low gene count values in
all follow-up timepoints. Moreover, 5/8 HIV-negative sub-
jects (62.5%) showed increases in gene richness during
follow-up.
Microbial species composition
Like in previous European populations, microbial species
positively correlated with higher gene richness included
Subdoligranulum spp., methanogenic archaea, several bu-
tyrate producers from the Ruminococcus, Dorea and Eubac-
terium genera, and Butyrivibrio crossotus (Fig. 5a).
Prevotella copri was negatively correlated with gene rich-
ness in this study, which is consistent with the compos-
itional nature of the microbiome in this Prevotella-rich
African population [33, 34]. An unclassified species from
genus Dorea was the unique taxa negatively correlated to
gene richness in the RHI group.
In a longitudinal evaluation, several microbial species
associated with gene richness were depleted in RHI
compared to HIV-negative individuals (Fig. 5b). In gen-
eral, such depletion occurred already at the first time-
point and in some cases (i.e., methanogenic archaea,
Ruminococcus champanellensis, R. flavencis) did not re-
cover during the available follow-up. Linear mixed
models only identified significant increases in Eubacter-
ium biforme and Collinsella aerofaciens in RHI and in-
creases in Dorea unclassified and Ruminococcus flavencis
in HIV-negative subjects. Consistent with previous re-
ports [23], subjects with RHI had higher counts of bac-
terial antioxidant enzymes like catalase, bacterioferritin,
glucose-6-phosphate dehydrogenase, or peroxiredoxin,
although this shotgun analysis was underpowered to
identify more granular differences (Additiona1 file 1:
Figure S6).
Fecal virus shedding
HIV-1 infection was associated with increased fecal
shedding of Adenovirus measured by RT-PCR. This was
observed in RHI (53% of subjects) but also in chronically
HIV-1-infected individuals, regardless of whether they
were ART-naïve (51%) or received ART (44%) (all
p values < 0.05, relative to 20% of HIV-1-negative sub-
jects) (Table 2). Conversely, increased shedding of Cyto-
megalovirus and Enterovirus was only observed in
CHI_noART subjects (6% and 21%, respectively), relative
to NEG (2% and 4%, respectively) (all p values < 0.05).
Human herpes viruses 6A, 6B, and 8 were not detected
in any individual, despite using proper extraction and
positive PCR controls.
Using 16S rRNA gene sequencing to assess bacterial
taxa, fecal Adenovirus shedding was linked to increased
relative abundance of an unclassified Mogibacteriaceae
genus and lower relative abundance of an unclassified
Erysipelotrichaceae genus. Cytomegalovirus shedding
was only linked to lower abundance of family Clostridia-
ceae. Enterovirus shedding was linked to lower abun-
dances of Parabacteroides, Akkermansia, and an
unclassified genus from the bacterial family Rikenella-
ceae as well as to higher abundance of an unclassified
(See figure on previous page.)
Fig. 3 Dynamics of bacterial clusters following HIV-1 infection. a Within group co-abundant bacterial genus clusters (SP1 to 7) obtained using 16S
rRNA gene sequencing. The color gradient is proportional to the mean of scaled individual relative abundance values (mean = 0, sd = 1) per
bacterial genera and study group. Dots show statistically significant differences in genus abundance relative to HIV-negative subjects (NEG). b
Linear mixed models of the longitudinal evolution of bacterial clusters in subjects with recent HIV-1 infection (RHI) and HIV-negative (NEG)
individuals. Horizontal axes show months after study enrollment. Each dot corresponds to a sample, and samples from the same individual
through follow-up are line-connected. Single dots correspond to individuals with no longitudinal follow-up. Thick black lines correspond to the
modeled slope of each bacterial cluster. Statistically significant differences from 0 (flat slope) are shown with asterisks. p values *< 0.1 and
**< 0.05. c Spearman’s correlation between bacterial clusters and immune markers measured in blood. The color gradient is proportional to the
Spearman’s rho value. Only unadjusted statistically significant correlations (p value < 0.05) are shown. CHI_ART, CHI_noART, and first available
samples from individuals in any of the RHI < 6, RHI > 6, and NEG groups were used to compute correlation values. Other immune markers
measured in blood include IgA, IgM, IgG2, and IgG4 for serological makers; EndoCab IgG and IgA ASCA for gut permeability; FABP2 for bacterial
translocation; IL7, IL13, GCSF, RANTES, MIP1 alpha, and beta for T cell function; IFN gamma, TNF alpha, and IL8 for Th1 pro-inflammatory
responses; TGF beta for anti-inflammatory responses; CD40 ligand and IL21 for B cell function, Eotaxin, IL5, sCD163, and IL15 for innate cells;
CXCL16 and IL1 beta for inflammation; B7H1, PDL2, and IL2R for immune activation; and EGF and VEGF for angiogenesis. Several markers were
also measured in feces although none of them showed significant correlations with bacterial clusters: sIgA, ANCA, and ASCA for serological
markers; EDNEPX, calprotectin, PMNE, lactoferrin, and S100A12 for neutrophil and eosinophil activation; and HBD2, zonulin, and alpha 1 antitrypsin
for enterocyte damage and gut permeability. No correlations were found between bacterial clusters and levels of CD4+ and CD8+ T cell
activation, exhaustion, and senescence in blood.
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genus from the family Elusimicrobiaceae (Additional file
1: Figure S7).
Adenovirus shedding was significantly associated with
higher FABP2 and IgG ASCA levels in blood and to
lower levels of IL10 and IgG2 (Additional file 1:
Figure S8). Enterovirus detection in feces was positively
associated to higher levels of IL13, IL8, FABP2, CXCL16,
CD40L, and EGF in blood and zonulin levels in feces
and to lower levels of MIG and sCD1643 in blood. Cyto-
megalovirus shedding was associated to higher IgA and
MCP1 and lower levels of IL15 in blood.
Discussion
This study shows that acute HIV-1 infection is followed
by increased fecal adenovirus shedding, which persists
during chronic HIV-1 infection and does not resolve
with ART. In genus-level analyses, HIV-1 infection is
followed by transient changes in the gut microbial richness
and composition, which are not HIV-specific. An HIV-1-as-
sociated microbiome signature—featuring depletion of
Akkermansia, Anaerovibrio, Bifidobacterium, and Clostrid-
ium—only becomes evident in chronically HIV-1-infected
subjects. Finer species-level shotgun metagenomics analyses
suggest an early and sustained depletion of methanogenic ar-
chaea and several fiber-consuming butyrate-producers fol-
lowing HIV-1 infection.
By using RT-PCR, we purposely performed a targeted
analysis of a discrete set of eukaryotic viruses with
known pathogenic potential, rather than a comprehen-
sive shotgun virome analysis. Most of the gut virome is
a
b
Fig. 4 Microbial gene richness in recently HIV-1-infected and HIV-negative subjects using shotgun metagenomics. a The leftmost density plot
shows a bimodal distribution of all samples according to their observed gene richness value, which enables their classification into low (LGC) and
high gene count (HGC). The rightmost density plot shows that HGCs are enriched in NEG, whereas RHI predominate in LGCs. b Longitudinal
evolution of microbial gene richness in RHI (in red) and NEG (in green). Each box represents an individual with its longitudinal follow-up samples
(timepoints 1, 4, and 9). The dark gray-colored area represents the LGC zone, whereas light gray-colored area represents the HGC zone
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composed by bacteriophages of uncertain pathogenicity,
and previous analyses using shotgun sequencing found
no relationship between the gut bacteriophage compos-
ition and HIV-1 [25] or SIV infection [35].
Our findings, however, are consistent with previous
studies in non-human primates, where SIV infection was
associated with expansion of the enteric virome with
minimal changes in the bacteriome [26, 35]. Using
RT-PCR, we observed that fecal Adenovirus shedding
not only was present in more than half of RHI subjects,
but also in subjects with chronic HIV-1 infection, being
rare in HIV-negative controls. In contrast, fecal CMV
and Enterovirus shedding was mostly observed in un-
treated chronically HIV-1-infected individuals, suggest-
ing that CMV shedding might require more prolonged
immune dysregulation to occur. Several intestinal
Fig. 5 Evolution of richness-associated microbial species in recently HIV-1-infected vs. HIV-negative subjects using shotgun metagenomics. a
Microbial species significantly (p < 0.05) associated with microbial gene richness in both study groups, Spearman’s correlation rho values (red is
for positive, blue is for negative correlation). b Relative abundance of richness-associated bacterial species over time (months 1, 4, and 9). p values
within each box compare month 1 to 4 area under the curves of subjects with recent HIV-1 infection (RHI) versus HIV-negative individuals (NEG).
Asterisks show slope values significantly different from 0 in linear mixed models for each bacteria and study group
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eukaryotic viral families including Adenovirus, CMV,
and Enteroviruses promote immune activation in the
context of HIV-1/SIV infection [26]. Indeed, Adenovirus,
Enterovirus, and CMV fecal shedding were linked to sev-
eral immune markers of mucus alteration (FABP2, IgG
ASCA, IgA, and MCP1), epithelial disruption (zonulin
and EGF), and T cell proliferation, activation, and infil-
tration (CXCL16, IL10, and CD40L), hence reinforcing
their role in the inflammatory response to HIV-1 infec-
tion. The persistence of fecal Adenovirus shedding in
ART-treated subjects is worrying for clinicians, because
it might be a relentless source of immune activation dif-
ficult to curtail with available treatments. Of note,
HHV-6 and HHV-8 were not related at all with gut
microbiome changes following HIV-1 infection. No dif-
ferences in eukaryotic viruses fecal shedding were
observed between males and females.
An intrinsic limitation of our study design is that we
did not prospectively screen HIV-negative subjects at
risk for HIV-1 infection. Thus, we missed the very early
events occurring between HIV-1 infection and diagnosis.
Bearing this limitation in mind, the “increase—plateau”
microbial richness dynamics observed in RHI and NEG
groups could be explained by a return to baseline values
after a transient richness depletion due to an external in-
sult. Microbiome richness kinetics in HIV-infected sub-
jects mirrored that of CD4+ T cell counts and were
inversed to HIV-1-RNA kinetics. However, the observation
of similar microbiome dynamics in HIV-negative individuals
shows that such changes were not HIV-1-specific. Of note,
most HIV-negative controls in our study were seeking med-
ical care due to fever and/or mononucleosis-like symptoms
when they were recruited into the study, and this possibly
affected microbial richness as well. More sensitive shotgun
metagenomics analyses suggested that early microbial gene
richness reductions resolved earlier in HIV-negative individ-
uals than in HIV-1-infected subjects, but larger studies are
needed to confirm this observation. Previous studies have
linked lower microbial gene richness to lower nadir CD4+ T
cell counts [32], but such variable was not collected in our
study. Nonetheless, we did not find any significant correl-
ation between gene richness and most recent CD4+ T cell
counts, neither for the RHI and NEG groups.
The gut microbial composition also experienced transient
longitudinal changes, with reductions in bacterial clusters
associated with TNF-mediated innate immune responses
and increases in certain butyrate-producing bacteria like
Odoribacter. Increased abundance of potentially pathogenic
Proteobacteria has been reported in chronic HIV-1 infected
individuals [5, 18, 28, 29] and non-human primates with
acute SIV infection [24], and members of the Enterobacteri-
aceae family have been associated to immune activation
and inflammation in vivo and ex vivo [5, 28]. However,
none of the gut microbiome changes observed in our study
was clear enough to be considered HIV-specific.
This study was performed in a Prevotella-rich African
population. The lack of Prevotella to Bacteroides shifts
or changes in the Firmicutes:Bacteroidetes ratio in longi-
tudinal follow-up provided further evidence against the
previously reported association between these parame-
ters and HIV-1 infection [20, 21, 36, 37]. We did not
collect information on same-sex relationships, a poten-
tial confounder in microbiome studies [22], because this
was a sensitive issue in local culture and all men re-
ported heterosexual sex in previous questionnaires.
There is extensive data demonstrating Prevotella pre-
dominance in African populations [33, 34], so the effect
of same-sex intercourse on the gut microbiome would
have been hard to discern in this study. Although signifi-
cant differences in diet have been described between Af-
rican and European populations and its role on the gut
flora [34], collecting information on diet was not in-
cluded in the original project design. Hence, we were
unable to test the effect of diet in relation to the gut
microbiota in this study. An interesting collateral, previ-
ously unexplored aspect of our study is that the micro-
bial species associated with gene richness in this African
population were almost identical to those described in
European populations [13, 23].
The only statistically significant association between the
gut microbiome composition and HIV-1 infection was a
reduction in Akkermansia, Anaerovibrio, Bifidobacterium,
and Clostridium in chronically HIV-1-infected subjects
relative to HIV-negative individuals. Interestingly, Bifido-
bacterium and Clostridium have anti-inflammatory ef-
fects, and have been previously associated with HIV-1
Table 2 Prevalence of fecal virus shedding
Recent HIV-1
infection
Chronic HIV-1 infection HIV-negative
ART-naive On ART
Adenovirus 26/49 (53.2%)** 36/71 (50.7%)** 12/27(44.4%)** 11/55 (20.0%)
Cytomegalovirus 3/49 (6.1%) 4/71 (5.6%)* 1/27 (3.7%) 1/55 (1.8%)
Enterovirus 1/43 (2.4%) 4/19 (21.1%)* 1/25 (4.0%) 2/45 (4.4%)
Human herpes virus 6A, 6B, and 8 0/49 (0%) 0/71 (0%) 0/71 (0%) 0/55 (0%)
Numbers (percent) of subjects with detectable virus in feces by qualitative commercial real-time PCR. To avoid ascertainment bias due to different follow-up
between groups, only the first fecal sample available for testing is used for comparison
*p < 0.1, **p < 0.05; Fisher’s pairwise comparisons relative to HIV-1 negative
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infection [38–40], so reductions in these genera might
contribute to chronic inflammation in HIV-1-infected
subjects. Akkermansia plays a key role in improved human
fat and sugar metabolism [41] and promotes CD8+ T
cell-mediated immune responses to anti-cancer immune
modulators like PD-1 and CTLA4 agonists [42]. Defects
in Akkermansia might thus be related to HIV-1-associated
metabolic disorders as well as to CD8+ T cell anergy. In
our study, Akkermansia and Clostridiaceae abundance
were negatively correlated with markers of microbial
translocation (sCD14), inflammation (IP10), and gut integ-
rity (fecal calprotectin). Interestingly, ART initiation was
not associated with improved abundance of such mi-
crobes. However, proper longitudinal studies are still
needed to assess the impact of ART on the microbiome.
To our knowledge, this is the most comprehensive
prospective study investigating the longitudinal impact
of HIV-1 infection in the gut microbiome in a hyper-
endemic area such as the Manhiça district in
Mozambique, which was previously reported to have
a 40% HIV-1 prevalence in adult population [43]. It
also incorporates cross-sectional comparisons with
chronic HIV-infected subjects, which have been highly
informative of the longer-term effects of HIV-1 infec-
tion in the gut microbiome. However, this study has a
number of limitations.
First, HIV-1-infected subjects were followed more
often than HIV-negative individuals and there was a sig-
nificant amount of loss to follow-up, particularly among
HIV-negative subjects. This could have led to ascertain-
ment biases and affected our ability to detect further
associations. Following healthy individuals in clinical tri-
als for prolonged periods of time in resource-limited set-
tings is very difficult due to a variety of structural
constraints [44]. Linear mixed models can partially ac-
count for information loss, but it is evident that lost to
follow-up adds uncertainty to our evaluations and might
have affected our observations. A second limitation is
that, due to the study design, we missed the hyperacute
phase of HIV infection. Such phases can only be studied
either through very large and costly HIV-negative pro-
spective screening programs, which are out of our reach,
or through controlled experiments in non-human pri-
mates, which might not always reflect events in humans.
A third limitation is that most HIV-negative subjects were
not completely healthy when they were recruited into the
study. However, this helped us recognize that the transient
changes observed in the gut microbiome of HIV-1-infected
subjects were not, in fact, HIV-1-specific. Fourth, shotgun
metagenomic data was only available for a subset of pro-
spectively followed HIV-1-infected and HIV-negative sub-
jects and was not available for chronic HIV-1-infected
subjects. Finally, we did not perform a formal comprehen-
sive virome analysis but, instead, focused on specific viruses
with known pathogenic potential. As mentioned before, this
strategy has advantages and limitations.
Conclusions
In conclusion, our study shows that HIV-1 infection is
followed by increased fecal Adenovirus shedding and by
transient, non-HIV-specific changes in the gut bacteriome.
Despite early resilience to change, an HIV-1-specific sig-
nature in the gut microbiome including depletion of
Akkermansia, Anaerovibrio, Bifidobacterium, and Clos-
tridium—previously associated with chronic inflamma-
tion, CD8+ T cell anergy, and metabolic disorders—can be
identified in chronically HIV-1-infected subjects. Longitu-
dinal studies addressing the ability of ART to prevent and/
or recover such changes are needed.
Methods
Experimental models and subjects’ details
Human subjects
This was a sub-study of a prospective observational cohort
study (The GAMA cohort Study) [30, 45] originally de-
signed to identify systemic and gastrointestinal inflamma-
tion biomarkers of recent HIV-1 infection. The study
population was enrolled between April 2013 and May
2014 at the Manhiça District Hospital (MDH), district of
Manhiça, Southern Mozambique. The study was approved
by local institutional review boards at the Barcelona Clinic
Hospital (2011/6264) and by the Ministry of Health of
Mozambique (461/CNBS/12). Written informed consent
was obtained from patients before participation.
This microbiome sub-study had two components
(Additional file 1: Figure S1):
(a) First, we conducted a prospective observational cohort
study to characterize the longitudinal changes
occurring in the fecal microbiome of individuals with
recent HIV-1 infection (RHI) and HIV-negative con-
trols (NEG) during at least 9months after their initial
HIV-1 assessment. Adults older than 18 years, who
were residents of the established district surveillance
system study area and who presented to the outpatient
clinic of the MDH for nonspecific febrile symptoms or
voluntary HIV counseling and testing were invited to
participate in the study.
(b) Second, data from this longitudinal cohort was
compared to a single evaluation from chronically HIV-
1-infected subjects followed at the outpatient HIV-1
clinic at the MDH, who were receiving antiretroviral
therapy (CHI_ART) or not (CHI_noART). For this
cross-sectional comparison, we divided the longitu-
dinal follow-up of RHI in two periods: before and after
the first 6months of follow-up (RHI≤6 and RHI > 6),
and only included data from the first sample available
Rocafort et al. Microbiome            (2019) 7:73 Page 11 of 17
from each period, as well as the first sample available
from each HIV-1 negative subject (NEG).
Pregnant women were not allowed to enter the study.
Diagnosis of recent HIV-1 Infection
Blood was collected by finger prick for HIV rapid antibody
testing with Determine HIV 1/2 (Abbott Laboratories,
Chicago, IL, USA). Positive results were confirmed with a
more specific Uni-Gold rapid test (Trinity Biotech Co.,
Wicklow, Ireland). Individuals with positive HIV-1 ser-
ology in both rapid tests were not eligible for enrollment
into the study and were referred for clinical management.
Recent HIV infection (RHI) was defined as a negative or
indeterminate rapid test serology (first test negative or
first test positive and second test negative) and positive
HIV-1 viremia by reverse transcriptase–polymerase chain
reaction on frozen plasma (Abbott Real-Time HIV-1
Assay, limit of detection 150 copies/mL). HIV-1 RNA test-
ing was performed by applying a multilevel pooling
scheme of 10 samples/pool as described before [46]. A
subgroup of HIV-negative (NEG) time-matched controls
was selected by computer randomization, which were also
prospectively followed and served as controls for RHI.
Study follow-up
Subjects with RHI were seen at months 1, 2, 3, 4, 6, 9, 12,
15, and 18 after study enrollment, whereas HIV-negative
controls were seen at months 1, 4, and 9. This was consid-
ered the only follow-up realistically feasible in otherwise
healthy subjects in the Mozambican setting. Medical con-
sultation and HIV counseling were provided at each med-
ical visit. Study participants received antibiotic treatment
as required according to their clinical status. They also
began ART when needed, according to the Mozambican
ART guidelines applicable at the time of the study (i.e.,
when CD4+ T cell counts were lower than 250 cells/mm3
or clinical complications requiring ART initiation oc-
curred). If subjects had to start antibiotics or ART, they
provided a last fecal sample and the study follow-up was
immediately terminated. Similarly, the study follow-up
was interrupted if women became pregnant. Only one
clinical and analytical assessment was performed in
chronically HIV-1-infected adults. In this pilot exploratory
study, no formal sample size calculation was performed.
Method details
Demographic and clinical data
Demographic and clinical data were collected in a spe-
cific questionnaire which included the study group to
which the patient belonged (RHI, NEG, CHI_ART, and
CHI_noART); the timepoint of follow-up in months; the
participant’s gender, age, weight, and height; his/her
CD4+ and CD8+ T cell counts; the CD4+/CD8+ ratio;
HIV-1 RNA levels; hemogram; body temperature;
whether fever was reported or not within the previous
24 h of sample collection; whether the patient reported
or not diarrhea the week before sample collection and
its severity; and information on pregnancy, antiretroviral
therapy, and antibiotic use.
The dataset also included information on a malaria
optic microscopic assessment performed the day of sam-
ple collection, whether the participant reported malaria
within the previous month of sample collection, the
presence of occult blood in feces, and the result of
microbiological tests in feces, including Giardia spp.,
Cryptosporidium spp., Entamoeba spp., Clostridium dif-
ficile toxin, as well as serologies for hepatitis B and C,
syphilis and Strongyloides stercoralis.
16S rRNA gene sequencing: DNA extraction, amplicon
generation and sequencing
Fecal DNA was extracted using the PowerSoil DNA Ex-
traction Kit (MO BIO Laboratories, Carlsbad, CA, USA).
The V3–V4 variable regions from the 16S rRNA gene
(amplicon size expected ~ 460 bp) were PCR-amplified
using the MiSeq rRNA Amplicon Sequencing protocol
and primers 16S_F 5′-(TCG TCG GCA GCG TCA GAT
GTG TAT AAG AGA CAG CCT ACG GGN GGC
WGC AG)-3′ and 16S_R 5′-(GTC TCG TGG GCT
CGG AGA TGT GTA TAA GAG ACA GGA CTA CHV
GGG TAT CTA ATC C)-3′. Amplification was per-
formed in 25 reactions containing 2.5 μl of non-diluted
DNA template, 0.8 μl of each primer at 10 μM, 8.4 μl of
DNA and RNA-free water, and 12.5 μl of KAPA HiFi
HotStart Ready Mix (containing KAPA HiFi HotStart
DNA Polymerase, buffer, MgCl2, and dNTPs, KAPA
Biosystems Inc., Wilmington, MA, USA). Thermal cyc-
ling conditions consisted of an initial denaturation step
(5 min at 95 °C), followed by 30 cycles of denaturation
(20 s at 98 °C), annealing (15 s at 69 °C), and extension
(15 s at 72 °C). These were followed by a final extension
step of 1 min at 72 °C. Once the desired amplicon was
confirmed in 1% agarose gel electrophoresis, the ampli-
fied DNA was stored at − 30 °C until library preparation.
Amplified DNA templates were cleaned from non-DNA
molecules and Illumina sequencing adapters, and dual
indices were attached using the Nextera XT Index Kit
(Illumina, Inc.) followed by the corresponding PCR amp-
lification program as described in the MiSeq 16S rRNA
gene Amplicon Sequencing protocol. After a second
round of cleanup, amplicons were quantified using the
Quant-iT™ PicoGreen® dsDNA Assay Kit (Invitrogen,
Carlsbad, MA, USA) and Nanodrop 1000 (Thermo Sci-
entific, DE, USA) and diluted in equimolar concentra-
tions (T4 nM) for further pooling. Sequencing was
performed on an Illumina MiSeqTM platform (Illumina,
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Inc.) according to the manufacturer’s specifications to gen-
erate paired-end reads of 300 base length in each direction.
Whole genome sequencing (WGS): library preparation and
sequencing
In addition to 16S rRNA gene sequencing, a subset of 54
samples was evaluated using shotgun fecal metagenomic
sequencing. Subjects chosen for shotgun sequencing
analysis had fecal samples available for testing at least at
months 1 and 4. If available, month 9 from these same
subjects was also sequenced. Extracted, non-diluted
DNA was fragmented with the Nextera-XT Illumina kit
(Illumina, Inc.) following the manufacturer’s instruc-
tions. One library of approximately 300 bp clone insert
sizes was constructed per sample. Samples were se-
quenced in an Illumina HiSeq sequencer (Illumina, Inc.).
16S rRNA gene sequence analysis
Raw Illumina MiSeq sequences were filtered using a
minimum quality threshold of Q20 in at least 50% of the
bases and a minimum sequence average quality of Q20.
The 1.9.1 version of Qiime (Quantitative Insights Into
Microbial Ecology) software pipeline [47] was used for
taxonomic classification of 16S rRNA gene sequences
contained in each sample, using GreenGenes 13.8 as the
reference database [48]. The first step was to join for-
ward and reverse reads per each sample using the join_
paired_ends.py script. The maximum percent differences
accepted in the overlapping region were set to 15. Reads
were then filtered to contain a maximum of 2 ambigu-
ous bases (N) using the split_libraries_fastq.py script. An
open-reference OTU picking approach was used to clus-
ter reads at 97% sequence similarity and construct oper-
ational taxonomic units (OTUs). Briefly, in this
pick_open_reference_otus.py approach, reads are clus-
tered against a reference sequence collection and reads
that do not hit any reference sequence are subsequently
clustered using a de novo clustering approach. We then
used the ChimeraSlayer [49] method in the parallel_i-
dentify_chimeric_seqs.py script to identify chimeric se-
quences using a PyNast reference from the GreenGenes
13.8 database. Finally, make_otu_table.py, filter_align-
ment.py and make_phylogeny.py scripts were used to
create final biom and phylogenetic tree files.
Metagenomic sequence analysis
Raw HiSeq sequences were filtered using Trimmomatic
[50]. Nextera adapters were removed, and reads were
trimmed enabling a minimum quality of Q30, a global
minimum length of 100 bp and using a sliding window
set at a minimum quality of Q20 for each 30-bp-long
consecutive segments. Human contamination was re-
moved by mapping filtered sequences against the human
genome and removing reads with an alignment quality
above Q20. Paired filtered reads were used for taxo-
nomic characterization of microbial communities using
MetaPhlan2 software with the default parameters [51].
Entire sets of filtered reads were aligned using Bowtie2 to
the integrated reference catalog of the human gut micro-
biome (IGC) (http://meta.genomics.cn/meta/home) [52].
Resulting alignments were then filtered with Samtools
[53] so that only reads with an alignment quality above
Q20 were kept. Additionally, chimeric and secondary
alignments were also removed. Eventually, a subset of six
million aligned reads was created per sample alignment to
ensure that results of gene KEGG (http://www.genome.jp/
kegg/) and metabolic pathway richness were comparable
between samples.
Detection of fecal virus shedding by qualitative RT-PCR
We selectively evaluated the presence of viruses with hu-
man pathogenic potential—i.e., Adenovirus (ADV), Cyto-
megalovirus (CMV), Human Herpesvirus (HHV) 6A and
6B, and 8 and Enterovirus (ETV)—in cryopreserved stool
DNA and RNA aliquots using commercial RT-PCR kits
and following the manufacturer’s instructions, including
adjustment of quantification using a sensitivity control
at 1 copy/μl. For ADV, the Adenovirus R-gene® kit (Bio-
Mérieux, Marcy-l’Étoile, France) was used. For CMV,
HHV 6A, 6B, and 8, specific probe/primer mixes for
RT-PCR assays (Virusys Corporation, TaneyTown, MD,
USA) were used in combination with the TaqMan® Gene
Expression Master Mix (Thermo Scientific, DE, USA) at
1/20 dilution. For ETV, fecal RNA was first extracted
from RNAlater®-cryopreserved fecal samples using the
Stool total RNA Purification Kit (Norgen Biotek, Cor-
poration, Thorold, Canada). Non-diluted fresh RNA
aliquots were directly used to perform qualitative
RT-PCR testing of enteroviruses using the Enterovirus
R-gene® Kit (BioMérieux, Marcy-l’Étoile, France).
Cytokine quantification in plasma
A total number of 51 cytokines were quantified in
plasma samples including general markers of inflamma-
tion, cell death and growth factors, angiogenesis, mono-
cyte function and mobility, T and B cell function,
neutrophil and eosinophil activation, enterocyte damage,
intestinal permeability, and microbial translocation. De-
tection of IL-1R antagonist, MCP-1, GCSF, IFN gamma,
IL-12, IL-13, IL-7, VEGF, MIG, RANTES, Eotaxin, MIP1
beta, IP-10, IL-2R, IFN alpha, IL-15, GMCSF, TNF alpha,
IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, MIP1 alpha, IL-17,
IL-8, and EGF were determined by using Human Cyto-
kine Magnetic 30-Plex panel (Invitrogen). Detection of
CD40 ligand and IL21 was performed by using the
Bio-Plex Pro Human Th17 cytokine assay (Bio-Rad). De-
tection of BAFF, CD27, and TNFR2 was performed by
using a Human Magnetic Luminex Screening Assay
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(R&D). Detection of sCD14, LBP, FABP 2, CRP, sCD163,
CXCL16, sCD23, B7H1, PD ligand 2, TRAIL, Fas ligand,
TGF beta 1 (R&D); IgG ASCA and IgA ASCA (Orgen-
tec); EndoCab IgG and EndoCab IgA (Hycult biotech);
and zonulin (Immundiagnostik) was assessed by
enzyme-linked immunosorbent assays (ELISA) proce-
dures. All quantifications were performed according to
the manufacturer’s instructions. Overflow and under
limit of detection values were validated for every analyte
as the double and the half of the detection limit,
respectively.
Additional quantification of general antibody types
and subtypes was also performed by ELISA using the
following antibodies: polyclonal affinity pure goat
anti-human IgA antibody α-Chain Specific (Jackson
Immunoresearch), mouse anti-human IgM antibody
(clone G20-127) (BD Pharmingen), mouse anti-human
IgG1 antibody (clone HP6069) (Life technology), mouse
anti-human IgG2 antibody (clone G18-21) (BD Pharmin-
gen™), mouse anti-human IgG3 Hinge (clone HP6050 )
(SouthernBiotech), mouse anti-human IgG4 antibody
(clone G17-4) (BD Pharmingen™), and polyclonal affini-
pure F(ab')2 fragment goat anti-human IgG, Fcγ frag-
ment specific.
Cytokine quantification in feces
Determinations in stool samples were performed by
ELISA commercial assays according to the manufac-
turer’s instructions for calprotectin, PMN-elastase, zonu-
lin, EDN/EPX, HBD2, secretory IgA1, α1–antitrypsin,
S100A12, and claudin (Immundiagnostik, Bensheim,
Germany); lactoferrin, ASCA, and pANCA (TechLab,
Blacksburg, USA).
Quantification and statistical analyses
Ecological analysis of gut microbiota
Bacterial taxonomic richness (observed richness and the
numeric richness estimators Chao1 and ACE) as well as
diversity/evenness measurements (Shannon and Simp-
son indices) were calculated using Vegan [54] and Biodi-
versityR [55] R packages, correspondingly. We modified
the Simpson index’s formula so that it was computed as
1/(1-Simpson concentration index). OTUs present
uniquely in one sample were filtered out to reduce noise.
For each of the samples, a subset of 5000 counts was
randomly selected using the rrarefy function from
Vegan, as representative of the entire sample sequence
set. Samples with less than 5000 counts were not consid-
ered for this ecological analysis.
Analysis of gut microbiota composition
All reads available were used to assess bacterial compos-
ition. OTUs present in less than 10 counts in 10% of
samples were filtered out. Then, OTU counts were
collapsed to different taxonomic levels using Phyloseq
[56] R package and the corresponding relative abun-
dance values were calculated.
Differences in overall microbiota composition were
evaluated using Non-Metric Multidimensional Scaling
(NMDS) ordination analysis on Bray-Curtis, Euclidean,
weighted UniFrac and unweighted UniFrac distances as
available in Phyloseq [56] and Vegan [54] R packages.
Permutational analysis of variance using Bray-Curtis dis-
tances as implemented in adonis function from the
Vegan R package was used to test the influence of differ-
ent metadata variables on microbiota composition simi-
larity measures. The PAM algorithm implemented in
Cluster [57] R package was used to test for the existence
of clusters of samples based on Bray-Curtis distance
matrices computed among samples.
Clustering of bacterial genera into co-abundance
groups was performed using hclust algorithm in R stats
package with ward.D2 methodology on an Euclidean dis-
tance matrix computed from a relative abundance table
of bacterial genera across groups. For each genus and
group, we calculated the mean value of all previously
scaled individual abundance percentages (force mean =
0 and sd = 1). A phylogenetic distance threshold of 0.8
allowed us to identify 7 different bacterial clusters on
the resulting dendrogram.
The LEfSe algorithm [58] was used to describe which
bacterial genera were significantly enriched or depleted
in association with positive and negative detection of
Adenovirus, Enterovirus and Cytomegalovirus in feces.
Comparisons were done using both the soft and the
strict statistical criterion regarding eukaryotic viral de-
tection and HIV-1 infection status. To increase sample
size in tested groups for the latter variable, samples from
RHI, CHI_ART and CHI_noART groups were catego-
rized as “Positive” meanwhile the samples form NEG
remained as “Negative”.
Analysis on gut microbiota’s gene richness and metabolic
functions
Filtered metagenomic sequences were mapped against
the Integrated Gene Catalog (IGC) [52] using the bwa
software [59]. Unique alignments with a minimum
quality of Q20 were selected for subsequent analyses.
To be able to compare the microbial gene content
across samples we used a downsampling size of six
million aligned sequences.
Gene richness was measured as the total number of
different genes present in the sample regardless of their
abundance and length. A minimum of one filtered
mapped sequence was set to consider the presence of a
gene. The copy number of each gene was estimated by
dividing the total reads mapping to a gene divided by
Rocafort et al. Microbiome            (2019) 7:73 Page 14 of 17
the gene’s length. A gene’s relative abundance was mea-
sured as its copy number divided by the sum of the total
gene copies in the sample. As in previous studies [13],
gene richness followed a bimodal distribution in a prob-
ability density function. The local minimum between the
two modes was considered the threshold value to classify
individuals in two groups according to their microbial
gene richness content: high gene counts (HGC) and low
gene counts (LGC).
Microbial functional profile
Genes found in shotgun metagenomes downsampled at
6M sequences were associated to one or multiple KEGG
categories according to the IGC reference database [52].
To measure KEGG abundances, all genes associated to
the same KEGG category were collapsed and their copy
numbers were summed. If a gene was associated to more
than one KEGG category, all categories were considered
separately. The relative abundance of KEGG categories
was measured as in the relative gene abundance ap-
proach detailed above. To analyze the metabolic path-
ways represented in all samples, we fed the HUMAnN
pipeline [60] with the KEGG copy number table. The
HUMAnN output included the relative abundances of
metabolic modules and pathways for each subject.
KEGG functions that were not associated to prokaryotic
or archaeal metabolism according to KEGG catalog in-
formation [61] were manually filtered out, to ensure that
only microbial functions were analyzed.
Fecal virus shedding analysis
Results derived from RT-PCR testing were used as pres-
ence/absence of viral DNA/RNA in feces. Comparison
of number of individuals with virus in feces among
groups at study entry was performed using Fisher’s exact
statistical test. To summarize results from tested sam-
ples from the same individual at different time points to
a single value per individual, we used two different cri-
teria: 1) if the first sample available from that given indi-
vidual was considered positive, that subject was positive,
2) if that given individual had at least 1 sample testing
positive along its follow-up, that subject was
considered positive.
Statistical analysis
Longitudinal changes in the RHI and NEG groups were
analyzed using linear mixed models. After visual inspec-
tion of raw data, we allowed for a biphasic modeling of
such longitudinal changes, allowing for an inflection
point at month 6 for RHI—as this is the accepted dur-
ation of recent HIV-1 infection [62], and at 4 months for
NEG subjects, because the parental GAMA study chose
to follow subjects at 1, 4, and 9 months and no 6-month
data was available. Linear mixed models from the first
phase were fitted using a random intercept, whereas the
last point from the first LMM was used as the intercept
for the second LMM. Separate statistics were then per-
formed for each LMM slope. In both cases, p values in-
dicated that the slope was significantly different from 0.
For the cross-sectional comparisons, intra-patient
comparisons at different time points were tested using
paired Wilcoxon Rank sum test, whereas comparisons
between two groups were tested using non-paired Wil-
coxon rank sum test. Comparisons between multiple
groups were statistically tested using Kruskal–Wallis and
post hoc pairwise tests corrected for multiple compari-
sons using Benjamini–Hochberg or false discovery rate
as needed. The Spearman’s correlation test was used to
test relation between numerical variables.
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